Markets:

Overview

News

Currencies

International

Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

7.130 +0.060 (+0.85%)

Streaming Delayed Price Updated: 2:54 PM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans ↗

October 17, 2025

Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest.

Via Benzinga

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive ↗

October 17, 2025

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Via Stocktwits

Topics Workforce

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 17, 2025

Via Benzinga

This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

October 17, 2025

Via Benzinga

Looking Into Kezar Life Sciences's Recent Short Interest ↗

October 29, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 17, 2025

Via Benzinga

Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗

October 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 16, 2025

Via Benzinga

Kezar Narrows Loss 37 Percent in Q2 ↗

August 13, 2025

Via The Motley Fool

FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study ↗

July 16, 2025

Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review.

Via Benzinga

Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate ↗

March 25, 2025

Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.

Via Benzinga

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study ↗

October 17, 2024

Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 09, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 09, 2024

Via Benzinga

Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗

October 09, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 08, 2024

Via Benzinga

FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths ↗

October 07, 2024

Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 30, 2024

Via Benzinga

Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug ↗

August 14, 2024

Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases.

Via Benzinga

KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024 ↗

August 13, 2024

KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024 ↗

May 09, 2024

KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

From Pennies to Fortunes: 3 Stocks Set to Make Millionaires ↗

March 27, 2024

Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries.

Via InvestorPlace

Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026 ↗

March 16, 2024

Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology.

Via InvestorPlace

KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023 ↗

March 14, 2024

KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗

March 02, 2024

Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...

Via Talk Markets

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond ↗

February 25, 2024

When you want to light your afterburners, these ideas will do the trick.

Via InvestorPlace

3 Penny Stocks Poised for an Unbelievable 1,000% Jump ↗

February 02, 2024

Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await.

Via InvestorPlace

As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits ↗

January 08, 2024

Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining.

Via Benzinga

Topics Initial Public Offering

Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth ↗

December 18, 2023

Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.